Institutions / Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB

CIK 1599882 · Institution · as of Dec 31, 2025
Portfolio value
$1.07B
Positions
94
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 94 →
CompanyClassValueShares% of portfolio
Regeneron Pharmaceuticals, Inc.$47.39M61,4004.4%
ELI LILLY & Co$45.37M42,2204.2%
Boston Scientific Corp$41.12M431,2073.8%
Medtronic plc$28.43M296,0002.7%
Intuitive Surgical Inc$27.19M48,0002.5%
Cooper Companies, Inc.$26.84M327,5002.5%
CVS HEALTH Corp$26.63M335,5002.5%
AbbVie Inc.$25.27M110,5752.4%
Glaukos Corp$23.71M210,0002.2%
Danaher Corp /De$22.67M99,0522.1%
Cencora Inc$21.40M63,3752.0%
Vera Therapeutics, Inc.$21.27M420,0002.0%
McKesson Corp$21.00M25,6002.0%
Axsome Therapeutics, Inc.$20.97M114,8002.0%
Alignment Healthcare, Inc.$19.94M1,009,4501.9%
Insmed Inc$19.77M113,5851.8%
Thermo Fisher Scientific Inc.$19.49M33,6401.8%
PROCEPT BioRobotics Corp$19.22M611,0001.8%
Alnylam Pharmaceuticals Inc$18.16M45,6751.7%
Unitedhealth Group Inc$18.12M54,9001.7%
Neurocrine Biosciences Inc$17.80M125,4911.7%
Insulet Corp$17.34M61,0001.6%
Doximity, Inc.$16.51M372,7501.5%
Edwards Lifesciences Corp$16.50M193,5001.5%
Nuvalent, Inc.$16.43M163,3501.5%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.